ImmuPharma plc (LON:IMM – Get Free Report) traded up 16.2% during trading on Thursday . The company traded as high as GBX 4.30 and last traded at GBX 4.30. Approximately 1,065,174 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 2,734,189 shares. The stock had previously closed at GBX 3.70.
ImmuPharma Stock Up 4.7%
The stock has a market capitalization of £28.08 million, a PE ratio of -12.16 and a beta of 3.02. The business’s 50-day moving average is GBX 4.22 and its two-hundred day moving average is GBX 5.44.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. As a group, analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
- MarketBeat Week in Review – 07/13- 07/17
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
